Novo Nordisk, Lilly see insatiable demand for weight-loss drugs

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years – limited only by their availability. The two companies have been the primary beneficiaries of the global boom in obesity drugs, ballooning their market values and reshaping expectations not just in the healthcare industry, but also for sellers of sugary snacks, nutritional aids and packaged foods. Sales of Wegovy and Ozempic for Novo and Lilly's Mounjaro surpassed expectations in the most recent quarter reported on Thursday, and both companies flagged their inability to manufacture enough supply to keep up with skyrocketing demand.